We also confirmed that TRPC3 was downregulated during the occurrence of BPD and that TRPC3 agonist was able to improve the disease progression of BPD, further confirming that TRPC3 participates in and regulates the occurrence of BPD through the NF‐κB signaling pathway. Here, NFKB1 is linked to bronchopulmonary dysplasia.